217 results
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry
8-K
EX-99.1
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry; the impact
8-K
EX-99.1
pjonsu
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
7zzw 3lpyuqtmt
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
2aye76 900kt2
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.2
lv4mj g38h
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
24swje9z93wkwnu
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
EX-99.1
pir6mfs659yj5knvnr
5 Jan 24
Regulation FD Disclosure
4:30pm
424B3
thlzqqzvo9cv4
13 Nov 23
Prospectus supplement
5:28pm
8-K
EX-99.2
wzy88pxqzwamwlq8bnsl
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
kztkn95hp 0q
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
8w7 wa8b1e1ko
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
eztdcz524s45epow3c
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
EX-99.2
awxlanm t5q
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
be6hbdm4r
17 Oct 23
Entry into a Material Definitive Agreement
8:32am